Table 6.
Ongoing clinical trials for HCC patients with HAIC+TKIs+PD-1/PD-L1 treatment.
| NCT Number | Phases | Title | Experimental: Treatment Group | Contral Group | Disease stage | Primary end point | Enrollment | |
|---|---|---|---|---|---|---|---|---|
| 1 | 04961918 | Phase 2 | The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC) | HAIC+Lenvatinib+Durvalumab | None | Advanced HCC | PFS | 36 |
| 2 | 05029973 | Phase 2 | HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Advanced Unresectable HCC | HAIC+Sintilimab+Bevacizumab Biosimilar | None | Advanced unresectable HCC | ORR | 30 |
| 3 | 04814043 | Phase 2 | PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial | Lenvatinib+PD-1 inhibitor | None | Potential resectable HCC | Conversion rate to resection | 57 |
| 4 | 05198609 | Phase 3 | Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial | FOLFOX-HAIC+Camrelizumab+Apatinib | Camrelizumab+Apatinib | HCC With PVTT | OS | 214 |
| 5 | 05166239 | Phase 2 | HAIC Combine With Lenvatinib and Camrelizumab for Advanced HCC With PVTT | HAIC+Lenvatinib+Camrelizumab | Lenvatinib+Camrelizumab | HCC with PVTT | 6 months PFS rate | 66 |
| 6 | 05135364 | Phase 2 | HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure | HAIC+TKI+Camrelizumab | None | Unresectable HCC | PFS | 48 |
| 7 | 05099848 | Phase 2 | A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma | HAIC+Apatinib+Camrelizumab | None | Unresected HCC | R0 resection rate | 20 |
| 8 | 04191889 | Phase 2 | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | HAIC++Apatinib+Camrelizumab | None | BCLC C-stage HCC | ORR | 84 |
| 9 | 04618367 | Not Applicable | HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT | HAIC+Lenvatinib+Sintilimab | None | HCC With PVTT | PFS rate at 6 months | 30 |
| 10 | 05003700 | Phase 2 | Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma | HAIC+Lenvatinib+Camrelizumab | None | Unresectable HCC | ORR | 48 |
HCC, Hepatocellular Carcinoma; HAIC, hepatic arterial infusion chemotherapy; TKIs, tyrosine kinase inhibitors; PD-1, programmed cell death protein-1; TACE, transarterial chemoembolization; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; FOLFOX HAIC, Oxaliplatin+Leucovorin+5-fluorouracil; ORR, objective response rate; OS, overall survival; PFS, progression free survival.